Calc Function

    • Calcs that help predict probability of a diseaseDiagnosis
    • Subcategory of 'Diagnosis' designed to be very sensitiveRule Out
    • Disease is diagnosed: prognosticate to guide treatmentPrognosis
    • Numerical inputs and outputsFormula
    • Med treatment and moreTreatment
    • Suggested protocolsAlgorithm

    Disease

    Select...

    Specialty

    Select...

    Chief Complaint

    Select...

    Organ System

    Select...

    Patent Pending

    Log In

    Show
    Forgot your password?
    Log In
    Or create a new account (it's free)

    Forgot Password?

    Enter your email address and we'll send you a link to reset your password.

    Get New Password

    Sign In Required

    To save favorites, you must log in.

    Creating an account is free, easy, and takes about 60 seconds.

    Already have an MDCalc account?

    Login to link your favorites and recently used calcs

    Show
    Forgot your password?
    Log In
    Or continue to Nuance

    Attention COACH STUDY participants:

    The principal investigators of the study request that you use the official version of the modified score here.

    NAFLD (Non-Alcoholic Fatty Liver Disease) Fibrosis Score

    Estimates amount of scarring in the liver based on several laboratory tests.
    When to Use
    Pearls/Pitfalls
    Why Use

    Patients who have been identified to have NAFLD.

    • Nonalcoholic fatty liver disease (NAFLD) is now the leading cause of chronic liver disease in the world.
    • Many NAFLD patients will have little progression in their disease, however a subset will progress to liver fibrosis and cirrhosis.
    • Patients studied to develop this score were screened for other causes of liver disease and were specifically evaluated closely for concomitant alcohol. Patients with already-decompensated liver disease by clinical or imaging evidence were also excluded.
    • Patients with NAFLD should have their fibrosis scores trended over time to evaluate for progression or stabilization.
    • The NAFLD can reduce liver biopsies in those patients predicted to have a low risk of fibrosis by their score: “a liver biopsy to determine severity of fibrosis would be required in only 25% of patients with NAFLD, that is, those identified as ‘indeterminate’.”
    • Patients with nonalcoholic fatty liver disease (NAFLD) and advanced liver cirrhosis are high risk for progression to end-stage liver disease.
    • Patients with known liver fibrosis should have their fibrosis trended over time to evaluate for progression or stabilization.
    years
    kg/m²
    No
    0
    Yes
    +1
    U/L
    U/L
    × 10³/µL
    g/dL

    Result:

    Please fill out required fields.

    Next Steps
    Evidence
    Creator Insights
    Dr. Paul Angulo

    About the Creator

    Paul Angulo, MD, (d. 2015) was a professor of medicine at the University of Kentucky after spending 12 years at the Mayo Clinic in Rochester, Minnesota, where he worked as associate professor of medicine. He specialized in general hepatology, non-alcoholic fatty liver disease, cholestatic liver disease, and autoimmune hepatitis. Dr. Angulo was on the editorial board of numerous medical journals and has authored more than 240 articles, abstracts, book reviews, and editorials.

    To view Dr. Paul Angulo's publications, visit PubMed

    Are you Dr. Paul Angulo? Send us a message to review your photo and bio, and find out how to submit Creator Insights!
    MDCalc loves calculator creators – researchers who, through intelligent and often complex methods, discover tools that describe scientific facts that can then be applied in practice. These are real scientific discoveries about the nature of the human body, which can be invaluable to physicians taking care of patients.
    Content Contributors
    About the Creator
    Dr. Paul Angulo
    Are you Dr. Paul Angulo?
    Also from MDCalc...
    Content Contributors